BioMarin Pharmaceutical(BMRN)
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research is in enzyme replacement therapies (ERTs). BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I (MPS I), by manufacturing laronidase (Aldurazyme, commercialized by Genzyme Corporation). BioMarin was also the first company to provide therapeutics for phenylketonuria (PKU).
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
*Currency in USD
Company Revenue
Quarterly
Quarterly
Annual
Annual
Projections
Mock data
Subscribe for the real data
Subscribe for the real data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name | Drug Name | Approved | Patent Expires | Indication |
|---|---|---|---|---|
| Aldurazyme | Laronidase | 2003-04-30 | ||
| Brineura | Cerliponase alfa | 2017-04-27 | ||
| Kuvan | Sapropterin | 2007-12-13 | 2024-2032 | |
| Naglazyme | Galsulfase | 2005-05-31 | ||
| Palynziq | Pegvaliase | 2018-05-24 | ||
| Roctavian | Valoctocogene roxaparvovec | 2023-06-29 | ||
| Vimizim | Elosulfase alfa | 2014-02-14 | ||
| Voxzogo | Vosoritide | 2021-11-19 | 2030-2036 |
1
2
>
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Indication |
|---|---|---|---|---|---|
1
2
3
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use